Harbin Pharmaceutical Group (600664) Fundamentals 2026 — P/E 49.0x, Revenue Analysis | SniperIQ
Harbin Pharmaceutical Group (600664) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥15.1B, trading at ¥5.98 on the SHH. This SniperIQ fundamentals page covers Harbin Pharmaceutical Group's valuation (P/E 49.0x, P/B 2.6x), profitability (net margin 1.9%), revenue (¥16.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Harbin Pharmaceutical Group's market cap?
Harbin Pharmaceutical Group (600664) has a market capitalization of approximately ¥15.1B, trading at ¥5.98 on the SHH. Market cap moves with the live share price.
What is Harbin Pharmaceutical Group's P/E ratio?
Harbin Pharmaceutical Group's trailing twelve-month P/E ratio is 49.0x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Harbin Pharmaceutical Group?
Harbin Pharmaceutical Group runs a net profit margin of 1.9%, a gross margin of 25.2%, and an operating margin of 3.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Harbin Pharmaceutical Group generate?
Harbin Pharmaceutical Group reported revenue of ¥16.0B for fiscal year 2025, with net income of ¥362M and earnings per share (EPS) of 0.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Harbin Pharmaceutical Group pay a dividend?
Harbin Pharmaceutical Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Harbin Pharmaceutical Group financially healthy?
Harbin Pharmaceutical Group carries a debt-to-equity ratio of 0.48x and a current ratio of 1.45x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Harbin Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Harbin Pharmaceutical Group (600664) the key facts are: market cap ¥15.1B, P/E 49.0x, revenue ¥16.0B, 52-week range 2.84-6.35. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Harbin Pharmaceutical Group's full fundamentals live
Get Harbin Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.